information on drugs
information on drugs with http://www.takeyourmeds.info

information on drugs

Take Your Meds

News for 24-Jan-12

Source: MedicineNet Healthy Kids General
5 Surprising Facts About Rheumatoid Arthritis

Source: MedicineNet Healthy Kids General
Health Tip: When It's Time to Call the Doctor About Bedwetting

Source: MedicineNet Healthy Kids General
Exercise Boosts Kids' Academic Performance

Source: MedicineNet Healthy Kids General
Are Poinsettia Plants Poisonous? Fact or Fiction?

Source: MedicineNet Healthy Kids General
Study: Preschools Forgo Free Play for Safety, Academics

Source: MedicineNet Healthy Kids General
Infant Formula Investigated in Baby Death

Source: MedicineNet Healthy Kids General
Bipolar Drug May Spur Weight Gain, Thyroid Problems: Review

Source: MedicineNet Healthy Kids General
Very Early Experiences May Stick in Memory

Source: MedicineNet Healthy Kids General
Infant Acetaminophen Dosage Change May Cause Confusion

Source: MedicineNet Healthy Kids General
Hungry Families Admit to 'Formula Stretching'

Search the Web
information on drugs
mental health
pharmaceutical research institute
self help tapes
australian pharmacies
pharmacy stores
drug
buy drugs
natural remedies
west pharmaceutical services

The Best information on drugs website

All the information on drugs information you need to know about is right here. Presented and researched by http://www.takeyourmeds.info. We've searched the information super highway far and wide to provide you with the best information on drugs site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
information on drugs.

information on drugs
information on drugs, , information on drugs, , information on drugs,
http://www.medmeet.com/
CLICK HERE RIGHT NOW

information on drugs

Take Your Meds
Most people skip taking their medication at certain times, this is bad for your health. Look to Take Your Meds on time and
Take Your Meds

Shopping for information on drugs



When you’re shopping for information on drugs you’ve come to the right place. We’re specialists in this information on drugs field. You can’t find exactly what you’re looking for on too many other sites, but you can here.

Well maybe that’s a slight exaggeration. We might not have got exactly what you’re looking for – information on drugs – but we know the very best websites to get it from. All you have to do is follow the links below. They’re the very best information on drugs sites you’re going to find anywhere, and they’re the ones we use ourselves when we want to get information or make a purchase.

How do we know they’re the best information on drugs websites available on the net today? Because we’ve spent months painstakingly researching the subject. We’ve visited every site about information on drugs we could find, and we’ve studied them to sort the good from the bad.

Look, we’re good at getting ranked well in search engines. information on drugs might be our big interest, but we’ll be the first to admit that out site doesn’t come anywhere near the quality of the websites we’re linking to. So what we suggest you do is follow one the links. You won’t be disappointed. Thanks for visiting our webpage, and please come back again one day. Next time you visit you might find that we’re the best information on drugs place online.

Drug Offers Hope to Cancer Patients

 by: ARA Content

(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community.

Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer.

In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow.

In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs.

Æterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer.

Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy.

Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce.

Æterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.

About The Author

Courtesy of ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

EDITOR'S NOTE: For more information about current trials call (888) 349-3232. For additional information, contact Paul Burroughs, director of communications, (418) 652-8525, Ext. 406. Neovastat is being developed by Æterna Laboratories of Quebec, Canada.

To learn more about anti-angiogenesis and Æterna Laboratories, visit the Æterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.

Google

http://www.medmeet.com/
Affordable Used Cars | Take It Right | Talk On The Net | Real Time Media On The Net | Medical Meetings

Fantasy Football   Talk On The Net   Take It Right